• Expertise

- Experta en estrategias omicas mediante espectrometría de masas avanzada (tecnología Orbitrap).

- Identificación y cuantificación relativa y absoluta de cualquier proteoma, sets de proteínas y de modificaciones post-translacionales (fosforilación, acetilación, glicosilación,etc.).

- Estudios de protein networks e interactomas proteicos.

- Experta en experimental design de proyectos de alta complejidad, preparación de cualquier proteoma para el posterior análisis mediante espectrometría de masas, en metodologías de cuantificación, en procesos de enriquecimiento proteico o de modificaciones post-translacionales, en métodos de data acquisition con el espectrómetro de masas, en análisis estadístico y análisis bioinformático.

- Identificación y cuantificación relativa y absoluta de metabolomas globales.

• Intereses científicos

- Investigación sobre las bases moleculares de la recaída de canceres hematológicos y de la respuesta a fármacos de inducción y de estabilización.

- Interés en el estudio de proteomas y metabolomas de cualquier sistema biológico y biomédico.

- Estudios moleculares de diagnostico, prognostico y respuesta a tratamientos en enfermedades raras.

- Diseño de estrategias omicas mediante espectrometría de masas para la rapida deteccion de biomarcadores en plasma o suero humano.

- Integracion de data de diferentes omicas.

CURRICULUM VITAE

PERSONAL INFORMATION

Family name, First name: Hernandez-Valladares Maria del Carmen

Date of birth: 17.06.1970

Sex: F

Nationality: Spanish

URL for personal web site: https://www.ugr.es/personal/maria-carmen-hernandez-valladares;

https://www.uib.no/en/persons/Maria.del.Carmen.Hernandez.Valladares;

https://www.researchgate.net/profile/Maria_Hernandez-Valladares;

https://scholar.google.com/citations?user=3WDvX3wAAAAJ&hl=en;

https://orcid.org/my-orcid?orcid=0000-0001-9347-7841

EDUCATION

2019 Master of Secondary School Education, speciality Physics and Chemistry, National long-distance University of Spain

2010 Master Public Health, University of Manchester, U.K.

2005 University Expert of Epidemiology and new applied technologies, National long-distance University of Spain and Institute of Health Carlos III, Madrid, Spain

1998 PhD: Disputation date: 29.09.1998. Centre of Protein Engineering, University of Liege, Belgium

1994 Master Organic Chemistry, Department of Organic Chemistry, Trinity College, Dublin, Ireland

1993 Bachelor of Chemistry, speciality of Biochemistry, University of Granada, Spain

SKILLS

Expert in mass spectrometry-based proteomics, phosphoproteomics, acetylomics, glycoproteomics, metabolomics and lipidomics. My main skills include complex experimental design, broad range of biochemistry experimental techniques (i.e., spectroscopy, kinetics, protein expression, structural biology, molecular biology and genomics), data analysis, statistics, data management, reports, presentations, article writing, funding proposal writing, networking, teaching, supervision, couching and training together with great social skills in order to be able to work efficiently in a pleasant environment

CURRENT AND PREVIOUS POSITIONS

2022- Senior investigator attached at the Institute of Biomedical Research ibs.GRANADA

2022- Senior investigator at the Department of Physical Chemistry at the University of Granada under a Maria Zambrano Senior contract 2021-2022 50% Associate Professor and leader of the Metabolomics Platform at the Clinical Sciences Department (K2) and 50% Chief engineer at Proteomics Facility of University of Bergen (PROBE), University of Bergen, Norway, University of Bergen, Norway

2016-2020 Postdoctoral scientist Department of Clinical Studies and Proteomics Facility of University of Bergen (PROBE), University of Bergen, Norway, University of Bergen, Norway

2014-2016 Researcher, Proteomics Facility of University of Bergen (PROBE), University of Bergen, Norway

2013 Maternal leave

2009-2012 Postdoctoral scientist, Department of Physiology, University of Liverpool, U.K.

2005-2009 Research Associate, Institute of Cell and Molecular Biology, Biopolis, Singapore

2004 Visiting Scientist, Queensland Medical Research Institute, Brisbane, Australia

1999-2003 Visiting Scientist, Institute of Livestock Research Institute-CGIAR group, Nairobi, Kenya

OTHER MOBILITY

2018-2019 Charles Perkins Centre, Mass Spectrometry facility of the University of Sydney, Australia (within the postdoctoral program at the University of Bergen)

FELLOWSHIPS AND AWARDS

2022 Maria Zambrano Senior at the University of Granada, Spain

2004 Visiting scientist at the Queensland Medical Research Institute, Brisbane, Australia thanks to a Human Frontier fellowship

1999-2001 Visiting scientist at the International Livestock Research Institute, Nairobi, Kenya, thanks to an award from the Spanish Agency for International Cooperation

1994-1998 Ph.D fellowship of the EU (Human Mobility Program); Centre of Protein Engineering, University of Liege, Belgium

MEMBERSHIPS OF ACADEMIES / SCIENTIFIC SOCIETIES

2021-2022 Faculty of Medicine Board Member, University of Bergen

2021- Committee member of the Initiative Program of the European Society of Proteomics (EuPA)

2010-2012 Member of the British Biochemical Society 2001-2002 Member of International Federation of University Women (IFUW)

1997-1998 Member of International Conferences on Bioinorganic Chemistry Society (ICBICS)

SUPERVISION OF GRADUATE STUDENTS AND RESEARCH FELLOWS

2022 One Erasmus student from the University of Granada, Spain, and one Ph.D student from the Diabetes Group at the Clinical Science Department, University of Bergen, Norway

2021 Two undergraduate students, Proteomics Facility of University of Bergen (PROBE), University of Bergen, Norway

2017-2018 One Master Student, Proteomics Facility of University of Bergen (PROBE), University of Bergen, Norway

2016 Two undergraduate students, Proteomics Facility of University of Bergen (PROBE), University of Bergen, Norway

2014-2015 One undergraduate students and two postdocs, Proteomics Facility of University of Bergen (PROBE), University of Bergen, Norway

2005-2009 One Ph.D student, one technician, two postdocs and two undergraduate students, Institute of Cell and Molecular Biology, Biopolis, Singapore

TEACHING ACTIVITIES

2022/2023 Physical Chemistry main course and Practicum for Chemistry Engineering degree at the Department of Physical Chemistry at the University of Granada; Practicum for Environmental Sciences degree at the Department of Physical Chemistry at the University of Granada

2021/2022 Practicum for Chemistry Engineering degree at the Department of Chemistry Physics at the University of Granada

2017 Technical Instrumentation, Pharmacy, University of Bergen, Norway

2015 Mass spectrometry proteomics, BioProt course, University of Bergen, Norway

2008-2009 Outreach program on Structural Biology, Institute of Cell and Molecular Biology, Biopolis, Singapore

2004 Plasmodium falciparum resistance in mouse models, Parasitology summer course, University of Granada, Spain

JOURNAL REVIEWER

Analytical Chemistry (IF 6.97; 2020); Nature Communications Biology (IF 14.92; 2020); International Journal of Nanomedicine (IF 6.4; 2020); Cancer Letters (IF 8.68; 2020) and Leukemia (IF 11.53; 2020)

PUBLICATIONS (1996-2022)

1. Hernandez-Valladares M., Galleni M., Frere J.M., Felici A., Perilli M., Franceschini N., Rossolini G. M., Oratore A. and Amicosante G. (1996). Overproduction and purification of the metallo-ß-lactamase from Aeromonas hydrophila AE036. Microbial Drug Resistance, 2: 253-256.

2. Hernandez-Valladares M., Felici A., Weber G., Adolph H.W., Zeppezauer M., Rossolini G. M., Amicosante G., Frere J.M. and Galleni M. (1997). Zn(II) dependence of the Aeromonas hydrophila AE036 metallo-ß-lactamase activity and stability. Biochemistry, 36: 11534-11541.

3. Paul Soto R., Hernandez-Valladares M., Galleni M., Bauer R., Zeppezauer M., Frere J.M. and Adolph H.W. (1998). Mono- and binuclear Zn-beta-lactamase from Bacteroides fragilis: catalytic and structural roles of the zinc ions. FEBS Letters, 438: 137-140.

4. Prosperi-Meys C., Llabres G., de Seny D., Paul Soto R., Hernandez-Valladares M., Laraky N., Frere J.M. and Galleni M. (1999). Interaction between class B ß-lactamases and suicide substrates of active-site serine ß-lactamases. FEBS Letters, 443: 109-111.

5. Paul Soto R., Bauer R., Frere J.M., Galleni M., Meyer-Klaucke W., Nolting H., Rossolini G.M., de Seny D., Hernandez-Valladares M., Zeppezauer M. and Adolph H.W. (1999). Mono- and binuclear Zn2+-ß-lactamases. Role of the conserved cysteine in the catalytic mechanism. Journal of Biological Chemistry, 274: 13242-13249.

6. Meyer-Klaucke W., Paul Soto R., Hernandez-Valladares M., Adolph H.W., Nolting H., Frere J.M. and Zeppezauer M. (1999). A comparison of Bacillus cereus and Aeromonas hydrophila Zn-ß-lactamases. Journal of Synchroton radiation, 6: 400-402.

7. Walter M.W., Hernandez-Valladares M., Adlington R.M., Amicosante G., Baldwin J.E., Frere J.M., Galleni M., Rossolini G.M. and Schofield C.J. (1999). Hydroxamate inhibitors of Aeromonas hydrophila AE036 metallo-ß-lactamase. Bioorganic Chemistry 27: 35-40.

8. Hernandez-Valladares M., Kiefer M., Heinz U., Paul Soto R., Meyer-Klaucke W., Nolting H., Zeppezauer M., Galleni M., Frere J.M., Rossolini G.M., Amicosante G. and Adolph H.W. (2000). Kinetic and spectroscopic characterization of the native and metal-substituted ß-lactamase from Aeromonas hydrophila AE036. FEBS Letters, 467: 221-225.

9. Hernandez-Valladares M., Zervosen A., Devreese B., Prosperi-Meys C., Adolph H.W., Mercuri P.S., Vanhove M., Amicosante G., Van Beeumen J., Frere J.M. and Galleni M. (2001). Inactivation of Aeromonas hydrophila metallo-ß-lactamase by cephamycins and moxalactam. European Journal of Biochemistry, 268: 3840-3850.

10. Hernandez-Valladares M., Naessens J., Gibson J.P., Musoke A.J., Nagda S., Rihet P., ole-MoiYoi O.K. and Iraqi F. (2004). Confirmation and dissection of QTL controlling resistance to malaria in mice. Mammalian Genome, 15(5): 390-398.

11. Hernandez-Valladares M., Rihet P., ole-MoiYoi O.K. and Iraqi F. (2004). Mapping of a new quantitative trait locus for resistance to malaria in mice by a comparative mapping approach with human chromosome 5q31-q33. Immunogenetics, 56: 115-117.

12. Hernandez-Valladares M., Naessens J., Nagda S., Musoke A.J., Rihet P., ole-MoiYoi O.K. and Iraqi F. (2004). Comparison of pathology in susceptible A/J and resistant C57BL/6J mice after infection with different sub-strains of Plasmodium chabaudi. Journal of Experimental Parasitology, 108: 134-41.

13. Flori L., Delahaye N.F., Iraqi F.A., Hernandez-Valladares M., Fumoux F. and Rihet P. (2005). TNF as a malaria candidate gene: polymorphism-screening and family-based association analysis of malaria attack and parasitemia in a population living in Burkina Faso. Genes and Immunity, 6:472-80.

14. Hernandez-Valladares M., Naessens J. and Iraqi F. (2005). Genetic resistance to malaria in mouse models. Trends in Parasitology, 21: 352-55.

15. Hernandez-Valladares M., Naessens J., Musoke A.J., Sekikawa K., Rihet P., ole-MoiYoi O.K., Busher P. and Iraqi F. (2006). Pathology of Tnf-deficient mice infected with Plasmodium chabaudi adami 408XZ. Journal of Experimental Parasitology, 114, 271-278.

16. Spielmann T., Dixon M.W.A., Hernandez-Valladares M., Hannemann M., Trenholme K.R. and Gardiner D.L. (2006). Reliable transfection of Plasmodium falciparum using non-commercial plasmid mini preparations. Int. J. Parasitology, 36, 1245-48.

17. Hernandez-Valladares M., Naessens J. and Iraqi F. (2007). Gene-knockout mice in malaria research: useful or misleading? Trends in Parasitology, 23, 522-6.

18. Nag S., Ma Q, Wang H., Chumnarnsilpa S., Lee W.L., Larsson M., Kannan B., Hernandez-Valladares M., Burtnick L.D., Robinson R.C. (2009). Ca2+ binding by domain 2 plays a critical role in the activation and stabilization of gelsolin. PNAS, 106, 13713-8.

19. Hernandez-Valladares M., Kim T., Kannan B., Tung A., Aguda A.H., Larsson M., Cooper J.A., Robinson R.C. (2010) Structural characterization of a capping protein interaction motif defines a family of actin filament regulators. Nat Struct Mol Biol. 17, 497-503.

20. Kannan, B. Larsson, M., Lee, W.L., Hernandez-Valladares M., Robinson, R.C. (2011) Actin polymerazation Dynamics-Insights from In vitro TIRF microscopy. Biophysics J, 3, 300-301.

21. Eisenberg, S., Laude, A.J., Beckett, A.J., Mageean, C.J., Aran, V., Hernandez-Valladares, M., Henis, Y.I. and Prior, I.A. (2013) The role of palmitoylation in regulating Ras localization and function. Bioch. Soc. Trans., 41, 79-83.

22. Hernandez-Valladares, M., Rihet, P. and Iraqi, F.A. (2014). Host susceptibility to malaria in human and mice: compatible approaches to identify potential resistant genes. Physiol Genomics, 46(1), 1-16.

23. Hernandez-Valladares, M., Aran, V., Prior, I.A. (2014) Quantitative proteomic analysis of compartmentalized signaling networks. Meth. Enzymol, 535, 309-25.

24. Cheung, V.W., Bo, X., Hernandez-Valladares, M., Go, M.K., Tung, A., Aguda, A.H., Robinson, R.C. and Yew, W.S. (2014). Identification of polyketide inhibitors targeting 3-dehydroquinate dehydratase in the shikimate pathway of Enterococcus faecalis. Plos One, 9(7): e103598.

25. Hernandez-Valladares, M. and Prior I. (2015). Comparative proteomic analysis of compartmentalised Ras signalling. Sci. Reports, 5: 17307

26. Aasebø, E., Forthun, R.B., Berven, F., Selheim, F. and Hernandez-Valladares, M. (2016). Global cell proteome profiling, phospho-signaling and quantitative proteomics for identification of new biomarkers in acute myeloid leukemia patients. Curr. Pharm. Biotechnol., 17(1): 52-70.

27. Aasebø, E., Mjaavatten, O., Vaudel, M., Farag, Y., Selheim, F., Berven, F., Bruserud, Ø. and Hernandez-Valladares, M. (2016). Freezing effects on the acute myeloide leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. J Proteomics, 154, 214-25.

28. Hernandez-Valladares, M., Aasebø, E., Mjaavatten, O., Vaudel, M., Bruserud, Ø., Berven, F. and Selheim, F. (2016). Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biol. Proced. Online, doi: 10.1186/s12575-016-0043-0. eCollection.

29. Tvedt, T.H.A., Reikvam, H., Aasebø, E., Hernandez-Valladares, M., Berven, F., Selheim, F. and Bruserud, Ø. How should quality of life assessment be used to evaluate elderly and unfit patients with acute myeloid leukemia? Qual. Life Res. (2016)

30. Hernandez-Valladares, M., Aasebø, E., Selheim, F., Berven, F. and Bruserud, Ø. (2016). Selecting sample preparation workflows for mass spectrometry-based proteomic and phosphoproteomic analysis of patient samples with acute myeloid leukemia. Proteomes, 4(3), doi: 10.3390/proteomes4030024.

31. Brenner, A.K., Aasebø, E., Hernandez-Valladares, M., Selheim, F., Berven, F. and Bruserud, Ø. (2017). Rethinking the role of osteoponin in human acute myeloid leukemia. Leuk. Lymphoma, 58(6), 1494-97.

32. Hernandez-Valladares, M., Vaudel, M., Bruserud, Ø., Selheim, F., Berven, F. and Bruserud, Ø (2017). Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers. Expert Rev. Proteomics, 14(8), 649-63.

33. Bruserud, Ø., Aasebø, E., Hernandez-Valladares, M, Tsykunova, G. and Reikvam, H. (2017). Therapeutic targeting of leukemic stem cells in acute myeloid leukemia, the biological background for possible strategies (2017). Expert Opin. Drug Discov., 12(10), 1053-1065.

34. Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications: Bamberg, Germany. 23-25 June, 2017. BMC Pharmacol Toxicol. 2017 Oct 10;18(Suppl 1):64

35. Aasebø E, Hernandez-Valladares M, Selheim F, Berven FS, Brenner AK, Bruserud Ø. Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators. Proteomes. 2018 Dec 20;7(1). pii: E1. doi: 10.3390/proteomes7010001.

36. Reis LC, Ramos-Sanchez EM, Petitto-Assis F, Nerland AH, Hernandez-Valladares M, Selheim F, Floeter-Winter LM, Goto H. Insulin-Like Growth Factor-I as an Effector Element of the Cytokine IL-4 in the Development of a Leishmania major Infection. Mediators Inflamm. 2018 Jul 29;2018:9787128. doi: 10.1155/2018/9787128. eCollection 2018.

37. Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Expert Opin Ther Targets. 2018 Jul;22(7):639-653. doi: 10.1080/14728222.2018.1487401.

38. Wangen R, Aasebø E, Trentani A, Døskeland SO, Bruserud Ø, Selheim F, Hernandez-Valladares M. Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome.Int J Mol Sci. 2018 Jan 19;19(1). pii: E296. doi: 10.3390/ijms19010296.

39. Aasebø E, Bartaula-Brevik S, Hernandez-Valladares M, Bruserud Ø. Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. Expert Rev Hematol. 2018 Jan;11(1):13-24. doi: 10.1080/17474086.2018.1407239.

40. Brenner AK, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Grønningsæter IS, Bartaula-Brevik S, Bruserud Ø. The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome. Cancers (Basel). 2019 Jan 10;11(1). pii: E73. doi: 10.3390/cancers11010073

41. Hernandez-Valladares M, Wangen R, Berven FS, Guldbrandsen A. Protein Post-Translational Modification Crosstalk in Acute Myeloid Leukemia Calls for Action. Cur Medic Chem, 2019, 26(28), 5317-5337

42. Nepstad I, Hatfield KJ, Grønningsæter IS, Aasebø E, Hernandez-Valladares M, Hagen KM, Rye KP, Berven FS, Selheim F, Reikvam H, Bruserud Ø. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transd Target Ther. 2019, 4:20, doi: 10.1038/s41392-019-0050-0

43. Aasebø E, Berven FS, Bartaula-Brevik S, Stokowy T, Hovland R, Vaudel M, Døskeland SO, McCormack E, Batth TS, Olsen JV, Bruserud Ø, Selheim F, Hernandez-Valladares M. Proteome and phosphoproteome changes associated with prognosis in acute myeloid leukemia. Cancers 2020, 12(3): 709, doi: 10.3390/cancers12030709

44. Aasebø E, Berven FS, Hovland R, Døskeland SO, Bruserud Ø, Selheim F, Hernandez-Valladares M. The progression of acute myeloid leukemia from first diagnosis to chemoresistant relapse: a comparison fo proteomic and phosphoproteomic profiles. Cancers 2020, 12(6): E1466, doi: 10.3390/cancers12061466

45. Hernandez-Valladares M, Bruserud Ø, Selheim F. The implementation of mass spectrometry-based proteomics workflows in clinical routines of acute myeloid leukemia: applicability and perspectives. Int. J. Mol.Sci. 2020, 21: 6830

46. Hernandez-Valladares M, Aasebø E, Berven FS, Selheim F, Bruserud Ø. Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation. Aging 2020, 12(24):24734-24777

47. Hernandez-Valladares M, Wangen R, Aasebø E, Reikvam H, Berven FS, Selheim F, Bruserud Ø. Proteomic studies of primary acute myeloid leukemia cells derived from patients before and during disease-stabilizing treatments based on all-trans retinoic acid and valproic acid. Cancers 2021, 13(9):2143

48. Bruserud Ø, Tsykunova G, Hernandez-Valladares M, Reikvam H, Tvedt THA. Therapeutic use of valproic acid and all-trans retinoic acid in acute myeloid leukemia-literature review and discussion of possible use in relapse after allogeneic stem cell transplantation. Pharmaceuticals 2021, 14(5):423

49. Aasebø E, Brenner AK, Hernandez-Valladares M, Birkeland E, Berven FS, Selheim F, Bruserud Ø. Proteomic comparison of bone marrow derived osteoblasts and mesenchymal stem cells. Int J Mol Sci. 2021, 22(11):5665

50. Grønningsæter IS, Reikvam H, Bartaula-Brevik S, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Tvedt Tor Henrik, Bruserud Ø, Hatfield KJ. Effects of the autophagy-inhibiting agent chloroquine on acute myeloid leukemia cells: characterization of patient heterogeneity. J Personal. Medicine 2021, 11(8):779

51. Aasebø E, Brenner AK, Hernandez-Valladares M, Birkeland E, Mjaavatten O, Reikvam H, Selheim F, Berven FS, Bruserud Ø. Patient heterogeneity in acute myeloid leukemia: leukemic cell communication by release of soluble mediators and its effects on mesenchymal stem cells. Diseases. 2021, 9(4):74

52. Aasebø E, Brenner AK, Hernandez-Valladares M, Birkeland E, Reikvam H, Selheim F, Berven FS, Bruserud Ø. Protein characterization of spontaneous stress-induced in vitro apoptosis of human acute myeloid leukemia cells; focus on patient heterogeneity and endoplasmic reticulum stress. Hemato. 2021, 2, 607-627

53. Gahan JM, Hernandez-Valladares M, Rentzsch F. The chromatin-regulating CoREST complex is animal specific and essential for development in the cnidarian Nematostella vectensis. BMC Biology 2022, 20(1):184

54. Reikvam H, Hemsing AL, Hernandez-Valladares M, Birkeland E. Proteomic approaches for untangling pharmacological targets in acute myeloid leukemia. Expert Review of Proteomics 2022, doi: 10.1080/14789450.2022.2067530

55. Lasse, N., Takayidza, G. Berven, F.S., Hernandez-Valladares, M. Comparing efficiency of lysis buffer solutions and sample preparation methods for liquid chromatography-mass spectrometry analysis of human cells and plasma. Molecules 2022, 27(11), 3390

Aplicaciones de LC-MS proteomics Shot-gun proteomics; PTM-proteomics; Targeted proteomics/Surequant; Structural proteomics/Cross-linking MS; Proteogenomics; Metaproteomics; Plasma/serum proteomics; Viral proteomics; Forensin proteomics; Paleoproteomics; Biomarker discovery proteomics

Guest Editor at Cancers/MDPI https://www.mdpi.com/journal/cancers/special_issues/9M8H7BT367